Every material Form 8-K Twist Bioscience Corp has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Twist Bioscience filed a prospectus supplement to register for resale shares issuable to Invenra Inc. under a Stock Purchase Agreement and Registration Rights Agreement, both dated February 11, 2026. The filing includes a legal opinion from Orrick, Herrington & Sutcliffe LLP, and the filing does not state the number of shares or any sale price. For shareholders, this is an administrative step that could allow Invenra to sell shares into the market.
Registration rights agreement and stock purchase agreement with Invenra Inc. are both dated February 11, 2026.
Company is filing a prospectus supplement to register resale of shares issuable under the stock purchase agreement.
Orrick, Herrington & Sutcliffe LLP opinion filed as Exhibit 5.1; the filing does not state the number of shares.
Twist Bioscience disclosed that Anthropic, PBC published a blog post on August 18, 2026, saying it had received data from a protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview. Anthropic said it chose Twist as one of its independent evaluators to rapidly produce these AI-designed proteins at scale and test them for binding. The filing gives no financial terms, revenue figures, or contract value, so its effect on shareholders is not quantified.
Anthropic published a blog post on August 18, 2026 describing a multi-arm protein design campaign against 15 targets.
The campaign used Claude Opus 4.8 and Mythos Preview.
Anthropic named Twist Bioscience as one of its independent evaluators to produce and test AI-designed proteins for binding.
The filing is furnished under Item 7.01 and gives no financial figures for the arrangement.
Twist Bioscience priced an upsized public offering of 3,125,000 common shares at $96.00 per share on August 4, 2026, for expected gross proceeds of $300.0 million. On August 5, 2026, the underwriters exercised in full their option to buy 468,750 additional shares, and the company expects net proceeds of about $327.1 million, with closing expected on or about August 6, 2026. The company says it will use the proceeds, together with existing cash, for research and development, manufacturing capacity expansion, product offerings, and working capital.
Priced 3,125,000 shares at $96.00 per share, with expected gross proceeds of $300.0 million (August 4, 2026)
Underwriters exercised in full their option to purchase 468,750 additional shares at $96.00 per share (August 5, 2026)
Expected net proceeds of about $327.1 million, including the option shares; closing expected on or about August 6, 2026
Offering made under a Form S-3 automatic shelf registration filed June 18, 2026; Goldman Sachs, William Blair, Leerink Partners and Guggenheim are the underwriters
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Twist Bioscience Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →